# An Efficacy and Safety Study of Long-Term Risperidone Microspheres in Participants With Schizophrenia

> **NCT00269919** · PHASE4 · COMPLETED · sponsor: **Janssen Korea, Ltd., Korea** · enrollment: 40 (actual)

## Conditions studied

- Schizophrenia
- Schizoaffective Disorder

## Interventions

- **DRUG:** Risperidone Long-Acting Injectable (RLAI)

## Key facts

- **NCT ID:** NCT00269919
- **Lead sponsor:** Janssen Korea, Ltd., Korea
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-08
- **Primary completion:** 2008-08
- **Final completion:** 2008-08
- **Target enrollment:** 40 (ACTUAL)
- **Last updated:** 2014-04-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00269919

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00269919, "An Efficacy and Safety Study of Long-Term Risperidone Microspheres in Participants With Schizophrenia". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT00269919. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*